KEFLEX (cephalexin) by Pragma Bio is [see microbiology ( )] . First approved in 1971.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
KEFLEX (cephalexin) is a first-generation cephalosporin antibiotic administered orally as a capsule that inhibits bacterial cell wall synthesis. It is indicated for infections caused by susceptible gram-positive and some gram-negative bacteria, including respiratory tract, skin, and urinary tract infections. The drug has been a foundational oral antibiotic since FDA approval in 1971.
As LOE approaches, KEFLEX brand teams face declining revenue and shrinking commercial headcount; career growth depends on generic optimization or transition to higher-margin products.
[see Microbiology ( )] .
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Oral Amoxicillin and Cephalexin PK/PD in Neonates
Cefadroxil and Cephalexin Drug Levels and Dosing in Pediatric Musculoskeletal Infections
A Study of Cephalexin Liquid in Healthy Participants
A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants
A Study of Cephalexin Suspension in Healthy Participants
Worked on KEFLEX at Pragma Bio? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
KEFLEX offers minimal career development; zero linked job openings reflect its mature, off-patent status. Career roles are limited to compliance, supply optimization, and generic cost management rather than growth-oriented commercial or clinical positions.